Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.
about
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor AgonistsTreatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directionsIncretin based therapies: a novel treatment approach for non-alcoholic fatty liver diseaseEffects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetesPhysiology of proglucagon peptides: role of glucagon and GLP-1 in health and diseaseIndirect effects of glucagon-like peptide-1 receptor agonist exendin-4 on the peripheral circadian clocks in miceHepatic steatosis and Type 2 diabetes: current and future treatment considerations.Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesPathophysiology of Non Alcoholic Fatty Liver DiseaseBerberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesisPertussis toxin, an inhibitor of G(αi) PCR, inhibits bile acid- and cytokine-induced apoptosis in primary rat hepatocytesLiraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trialSafety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data.Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.Modern approach to the clinical management of non-alcoholic fatty liver diseaseTranslational approaches: from fatty liver to non-alcoholic steatohepatitis.Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy.Exendin-4 Improves Nonalcoholic Fatty Liver Disease by Regulating Glucose Transporter 4 Expression in ob/ob Mice.Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J miceDPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus.Insulin concentration modulates hepatic lipid accumulation in mice in part via transcriptional regulation of fatty acid transport proteins.Hepatic portal vein denervation impairs oral glucose tolerance but not exenatide's effect on glycemia.Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammationGLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden miceImproved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.Mitigation of autophagy ameliorates hepatocellular damage following ischemia-reperfusion injury in murine steatotic liver.Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.A 25-year-old woman with type 2 diabetes and liver disease.Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study.Effect of vildagliptin on hepatic steatosis.Dipeptidyl peptidase-4 inhibition ameliorates Western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function.Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targetsEfficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injuryGenetic determinants of pig birth weight variability.Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.Pleiotropic effects of incretins
P2860
Q26749495-57789622-67AE-43EB-86B0-389E57BBB68CQ26751258-31AC1CB2-45E7-43DA-9895-5EB0B4BFD283Q26827183-86CF2BB9-B3BF-404C-A5F5-7F5BF8DF8715Q27025423-AEA03D16-F1F5-4DDC-9C2A-4D5FE13FA4BAQ27027920-A9136CD4-93BA-4C3F-A15E-62AB0A757C21Q27301386-19008DEE-0F4C-4407-9411-7249E099E7BEQ27691399-722EF6F5-A272-4F39-A11A-BAC5CF3D10BBQ28067465-959A0FC8-AE7F-49FD-A639-41FF57DC1E6EQ28070011-96134801-AE0A-4076-9AF4-3E9A7F1A5946Q28477076-7AD2CBAC-7D2B-4655-B779-07E70F2966B1Q28482165-3F97C485-0596-4EAC-8B06-CB04917929C2Q28661700-F921509B-4398-42F9-A253-2F18D4AC64EEQ30577903-A29A5299-5DA4-4AB5-9280-7B3F1124EA1BQ30622511-24E4DEFA-697E-480D-A9D8-18B75D07B63BQ31149434-5CB8CD8A-9097-46A5-A3AA-D7258775FD66Q33603384-1528352F-C68C-4835-874C-2453148EAFF9Q33802278-3D1BDFB2-84A0-42BD-9F64-C525FB1531D8Q33886923-443042E9-1EF1-4D40-A28C-7C2CF079AD2CQ33958697-8E81730F-05FC-44A9-A75F-3383ADFEB066Q33970970-8BF16336-5397-40B0-B891-E7F5B7323B33Q34034795-0FDB123C-FBBA-435C-9854-55028AD30B64Q34097903-1B4AD0B7-3F54-4F46-8281-F4390D505C4DQ34170885-CD46B2FB-4393-4D3F-A654-BDE5DFD3C802Q34237983-2674A218-83E2-4FB7-8B4C-579839595D82Q34321195-C1756983-83DC-4E77-B72F-0756A2F080DBQ34355968-0BB67D97-D76D-468C-9404-FB701E687E4EQ34405101-9595005F-CFF6-4680-88F0-68C1767893F2Q34469947-E8F6DDC7-35CA-4DFC-A027-79926EDA9CEDQ34510307-3AA95533-08B9-4D46-B733-979FB0EE9609Q34627493-150F527C-B368-4479-BB43-43C119CC9D72Q34718822-3FFA2E78-EFF2-4AAB-8B30-4963D7A364ECQ34975050-D6F32B0F-6724-48D3-9FC1-144146F1A5F6Q35192176-2042F4D5-03FA-4882-AAEC-654819CA9A03Q35442079-309B29F8-2ADE-45A5-82FA-B7F93937513FQ35630861-79A3078C-3A43-49EC-A5DA-114394CE1546Q35668745-F4108F1F-2ED2-4BD4-9E27-632C2C879039Q35849028-C3737102-B3BE-40E8-8C8D-C22A6EFC55BFQ35907693-484C66AF-D8B9-4F9D-AEB1-4F4ECA361F3EQ35925169-267279C0-22E8-4AC7-B798-68197509CEB3Q35968092-4B3BCB8F-F7E3-4485-BEF3-FC43AC64ABB9
P2860
Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Glucagon-like peptide-1 recept ...... the insulin signaling pathway.
@en
type
label
Glucagon-like peptide-1 recept ...... the insulin signaling pathway.
@en
prefLabel
Glucagon-like peptide-1 recept ...... the insulin signaling pathway.
@en
P2093
P2860
P356
P1433
P1476
Glucagon-like peptide-1 recept ...... the insulin signaling pathway.
@en
P2093
Arash Grakoui
Frank A Anania
Jamie Mells
Jeffrey Handy
Neeraj Kumar Saxena
Nitika Arora Gupta
Richard M Dunham
P2860
P304
P356
10.1002/HEP.23569
P407
P577
2010-05-01T00:00:00Z